Two hundred and seventy-seven patients who had received gold sodium thiomalate (GST), were included in a retrospective study to identify those factors that might have influenced the development of side effects. Fifty-one per cent of patients were excluded due to side effects, especially skin rash, which affected 59% of those excluded. The duration of disease when GST therapy was commenced, female sex, and a history of smoking were identified as factors influencing the development of certain side effects. There was a high incidence of skin rash in smokers. Of 99 smokers, 40% developed dermatitis, whereas in 109 non-smokers, only 17% developed a rash (p less than 0.001). Other factors such as age, weight, and concurrent drug therapy, biochemical, haematological and immunological data, do not predict development of toxicity to GST.
No takes yet. Share an insight, caveat, or question.
Kay et al. (1987) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: